BACKGROUND: Methicillin-resistant Staphylococus aureus (MRSA) is an important nosocomial and community-associated (CA) pathogen. Recently, a variant of the MRSA USA300 clone emerged and disseminated in South America, causing important clinical problems. METHODS: S. aureus isolates were prospectively collected (2006-2008) from 32 tertiary hospitals in Colombia, Ecuador, Peru, and Venezuela. MRSA isolates were subjected to antimicrobial susceptibility testing and pulsed-field gel electrophoresis and were categorized as health care-associated (HA)-like or CA-like clones on the basis of genotypic characteristics and detection of genes encoding Panton-Valentine leukocidin and staphylococcal cassette chromosome (SCC) mec IV. In addition, multilocus sequence typing of representative isolates of each major CA-MRSA pulsotype was performed, and the presence of USA300-associated toxins and the arcA gene was investigated for all isolates categorized as CA-MRSA. RESULTS: A total of 1570 S. aureus were included; 651 were MRSA (41%)--with the highest rate of MRSA isolation in Peru (62%) and the lowest in Venezuela (26%)--and 71%, 27%, and 2% were classified as HA-like, CA-like, and non-CA/HA-like clones, respectively. Only 9 MRSA isolates were confirmed to have reduced susceptibility to glycopeptides (glycopeptide-intermediate S. aureus phenotype). The most common pulsotype (designated ComA) among the CA-like MRSA strains was found in 96% of isolates, with the majority (81%) having a < or =6-band difference with the USA300-0114 strain. Representative isolates of this clone were sequence type 8; however, unlike the USA300-0114 strain, they harbored a different SCCmec IV subtype and lacked arcA (an indicator of the arginine catabolic mobile element). CONCLUSION: A variant CA-MRSA USA300 clone has become established in South America and, in some countries, is endemic in hospital settings.
BACKGROUND:Methicillin-resistant Staphylococus aureus (MRSA) is an important nosocomial and community-associated (CA) pathogen. Recently, a variant of the MRSA USA300 clone emerged and disseminated in South America, causing important clinical problems. METHODS:S. aureus isolates were prospectively collected (2006-2008) from 32 tertiary hospitals in Colombia, Ecuador, Peru, and Venezuela. MRSA isolates were subjected to antimicrobial susceptibility testing and pulsed-field gel electrophoresis and were categorized as health care-associated (HA)-like or CA-like clones on the basis of genotypic characteristics and detection of genes encoding Panton-Valentine leukocidin and staphylococcal cassette chromosome (SCC) mec IV. In addition, multilocus sequence typing of representative isolates of each major CA-MRSA pulsotype was performed, and the presence of USA300-associated toxins and the arcA gene was investigated for all isolates categorized as CA-MRSA. RESULTS: A total of 1570 S. aureus were included; 651 were MRSA (41%)--with the highest rate of MRSA isolation in Peru (62%) and the lowest in Venezuela (26%)--and 71%, 27%, and 2% were classified as HA-like, CA-like, and non-CA/HA-like clones, respectively. Only 9 MRSA isolates were confirmed to have reduced susceptibility to glycopeptides (glycopeptide-intermediate S. aureus phenotype). The most common pulsotype (designated ComA) among the CA-like MRSA strains was found in 96% of isolates, with the majority (81%) having a < or =6-band difference with the USA300-0114 strain. Representative isolates of this clone were sequence type 8; however, unlike the USA300-0114 strain, they harbored a different SCCmec IV subtype and lacked arcA (an indicator of the arginine catabolic mobile element). CONCLUSION: A variant CA-MRSA USA300 clone has become established in South America and, in some countries, is endemic in hospital settings.
Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948
Authors: T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema Journal: J Clin Microbiol Date: 2001-07 Impact factor: 5.948
Authors: S Monecke; H Nitschke; P Slickers; R Ehricht; W Swanston; M Manjunath; R Roberts; P E Akpaka Journal: Eur J Clin Microbiol Infect Dis Date: 2011-11-09 Impact factor: 3.267
Authors: A Sanchini; F Campanile; M Monaco; V Cafiso; J-P Rasigade; F Laurent; J Etienne; S Stefani; A Pantosti Journal: Eur J Clin Microbiol Infect Dis Date: 2011-04-17 Impact factor: 3.267
Authors: María E Velazquez-Meza; Jacobo Ayala-Gaytán; María N Carnalla-Barajas; Araceli Soto-Noguerón; Claudia E Guajardo-Lara; Gabriela Echaniz-Aviles Journal: J Clin Microbiol Date: 2011-06-08 Impact factor: 5.948
Authors: Abraham Pulido-Cejudo; Mario Guzmán-Gutierrez; Abel Jalife-Montaño; Alejandro Ortiz-Covarrubias; Jose Luis Martínez-Ordaz; Héctor Faustino Noyola-Villalobos; Luis Mauricio Hurtado-López Journal: Ther Adv Infect Dis Date: 2017-08-31
Authors: Paul J Planet; Lorena Diaz; Sergios-Orestis Kolokotronis; Apurva Narechania; Jinnethe Reyes; Galen Xing; Sandra Rincon; Hannah Smith; Diana Panesso; Chanelle Ryan; Dylan P Smith; Manuel Guzman; Jeannete Zurita; Robert Sebra; Gintaras Deikus; Rathel L Nolan; Fred C Tenover; George M Weinstock; D Ashley Robinson; Cesar A Arias Journal: J Infect Dis Date: 2015-06-05 Impact factor: 5.226
Authors: Rafael Mendo-Lopez; Luis Jasso; Ximena Guevara; Aurora Lizeth Astocondor; Saul Alejos; Ana C Bardossy; Tyler Prentiss; Marcus J Zervos; Jan Jacobs; Coralith García Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: M Sassi; B Felden; M Revest; P Tattevin; Y Augagneur; P-Y Donnio Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-02 Impact factor: 3.267